A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis



Status:Not yet recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 100
Updated:8/15/2018
Start Date:October 2018
End Date:October 2019
Contact:Stacy Mach
Email:stacy.mach@nyumc.org
Phone:929 455 5539

Use our guide to learn which trials are right for you!

This is a prospective, randomized clinical trial looking to determine the role of
prophylactic treatment with topical corticosteroids in preventing recurrences in patients
with a history of infectious epithelial keratitis, stromal keratitis,endotheliitis, or
iridocyclitis. Patients will be enrolled to one of two treatment arms: Control arm: oral
acyclovir 400 mg BID OR valacyclovir 500 mg daily or Study arm: oral acyclovir 400 mg BID OR
valacyclovir 500 mg qdaily + topical corticosteroid eye drops.


Inclusion Criteria:

- Subject capable of giving informed consent and if not, an acceptable surrogate capable
of giving informed consent on behalf of the subject.

- Diagnosed with a history of herpetic eye disease

- Three or more episodes of HSV keratitis based on medical record documentation of
episodes with infectious epithelial keratitis, immune stromal keratitis with or
without epithelial ulceration, endothelitis, or iridocyclitis.

- Prior history of HSV keratitis based on medical record documentation of episode of
infectious epithelial keratitis, immune stromal keratitis with or without epithelial
ulceration, endothelitis, or iridocyclitis and corneal scarring in the central 4mm
zone.

Exclusion Criteria:

- Persons who are pregnant or nursing or intend to become pregnant or nurse in the next
one year.

- Allergy to acyclovir, fluoromethalone, loteprednol, prednisolone acetate, prednisolone
sodium phosphate, or any components of the formulations.

- Persons who are incarcerated.

- Unable to give informed consent or have an acceptable surrogate capable of giving
informed consent on behalf of the subject.

- Persons with systemic medical problems who do not agree to have continued medical
follow-up.

- History of topical corticosteroids to the eyelids or ocular surface of the involved
eye within the prior 30 days prior to enrollment.

- Patients with 3 or more episodes of uveitis in the past 12 months.

- History of keratoplasy or keratorefractive surgery of the involved eye.

- History of open or closed angle glaucoma or ocular hypertension on gtts.

- History of systemic steroid use within the prior 30 days.

- Unable to comply with the study protocol or in the opinion of the investigator would
not be a candidate for participation.

- Persons who are unable to instill gtts despite training/caregiver.
We found this trial at
1
site
550 1st Ave
New York, New York 10016
(212) 263-7300
Principal Investigator: Leela Raju, MD
Phone: 929-455-5539
New York University School of Medicine NYU School of Medicine has a proud history that...
?
mi
from
New York, NY
Click here to add this to my saved trials